In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics.

The in vivo biodistribution and pharmacokinetics of silica nanoparticles (SiO(2)) with systematically varied geometries, porosities, and surface characteristics were investigated in immune-competent CD-1 mice via the intravenous injection. The nanoparticles were taken up extensively by the liver and spleen. Mesoporous SiO(2) exhibited higher accumulation in the lung than nonporous SiO(2) of similar size. This accumulation was reduced by primary amine modification of the nanoparticles. High aspect ratio, amine-modified mesoporous nanorods showed enhanced lung accumulation compared to amine-modified mesoporous nanospheres. Accumulation of the nanoparticles was mainly caused by passive entrapment in the discontinuous openings in the endothelium of the liver and spleen or in the pulmonary capillaries, and was highly dependent on nanoparticle hydrodynamic size in circulation. The SiO(2) were likely internalized by the reticulo-endothelial system (RES) following physical sequestration in the liver and spleen. The nanoparticles that were transiently associated with the lung were re-distributed out of this organ without significant internalization. Pharmacokinetic analysis showed that all SiO(2) were rapidly cleared from systemic circulation. Amine-modified or nonporous nanoparticles possessed a higher volume of distribution at steady state than their pristine counterparts or mesoporous SiO(2). In all, surface characteristics and porosity played important roles in influencing SiO(2) biodistribution and pharmacokinetics. Increasing the aspect ratio of amine-modified mesoporous SiO(2) from 1 to 8 resulted in increased accumulation in the lung.

[1]  Liyi Shi,et al.  Biodistribution and toxicity of intravenously administered silica nanoparticles in mice , 2010, Archives of Toxicology.

[2]  Victor S-Y Lin,et al.  Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. , 2011, ACS nano.

[3]  Yaping Li,et al.  In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. , 2011, Small.

[4]  D. Discher,et al.  Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.

[5]  Keishiro Tomoda,et al.  Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. , 2008, Colloids and surfaces. B, Biointerfaces.

[6]  Hamidreza Ghandehari,et al.  Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. , 2011, ACS nano.

[7]  I. Sokolov,et al.  Novel fluorescent silica nanoparticles: towards ultrabright silica nanoparticles. , 2008, Small.

[8]  J. Perel,et al.  Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[9]  Hamidreza Ghandehari,et al.  Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. , 2012, ACS nano.

[10]  Linlin Li,et al.  Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery , 2012, Advanced materials.

[11]  Mark Voorneveld,et al.  Preparation , 2018, Games Econ. Behav..

[12]  Robert Langer,et al.  The biocompatibility of mesoporous silicates. , 2008, Biomaterials.

[13]  Cecilia Sahlgren,et al.  Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. , 2012, Nanomedicine.

[14]  Chin-Tu Chen,et al.  Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. , 2010, Biomaterials.

[15]  K. Yadav,et al.  Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles. , 2011, PDA journal of pharmaceutical science and technology.

[16]  Y. Hung,et al.  Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells , 2009 .

[17]  V. S. Lin,et al.  Mesoporous silica nanoparticles deliver DNA and chemicals into plants. , 2007, Nature nanotechnology.

[18]  Chung-Yuan Mou,et al.  Mesoporous silica nanoparticles as nanocarriers. , 2011, Chemical communications.

[19]  B. Shin,et al.  Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  Victor S-Y Lin,et al.  Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. , 2005, Angewandte Chemie.

[21]  Zongxi Li,et al.  Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. , 2010, Small.

[22]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[23]  Yasuo Yoshioka,et al.  Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. , 2011, Nature nanotechnology.

[24]  Hamidreza Ghandehari,et al.  Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  Chen Chang,et al.  High-contrast paramagnetic fluorescent mesoporous silica nanorods as a multifunctional cell-imaging probe. , 2008, Small.

[26]  F. Szoka,et al.  Dependence of pharmacokinetics and biodistribution on polymer architecture: effect of cyclic versus linear polymers. , 2009, Journal of the American Chemical Society.

[27]  Chung-Yuan Mou,et al.  Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. , 2008, Small.

[28]  Samir Mitragotri,et al.  Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  Ji Guo,et al.  Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[30]  E. W. Meijer,et al.  Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Linlin Li,et al.  Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery , 2012, Advanced materials.

[32]  Dong Chen,et al.  The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. , 2011, ACS nano.

[33]  Hamidreza Ghandehari,et al.  Cellular uptake and cytotoxicity of silica nanotubes. , 2008, Nano letters.

[34]  Indrajit Roy,et al.  In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. , 2010, ACS nano.

[35]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. , 2008, Advanced drug delivery reviews.

[36]  L. Huang,et al.  Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. , 1992, Biochimica et biophysica acta.

[37]  A. Maitra,et al.  Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. , 2002, International journal of pharmaceutics.